



Heart Failure Society of America (HFSA) 2025 Annual Scientific Meeting

September 26-29, 2025; Minneapolis, MN; Resource Hub – Draft

Welcome to our resource hub for Heart Failure Society of America Annual Scientific Meeting 2025 (HFSA)! This is a one-stop-shop for all your HFSA 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting. The HFSA Annual Scientific Meeting 2025 is a meeting where heart failure science, research, and practical management will be shared, and also provides many networking and connection opportunities.

Table of Contents

[Day-of Conference Reports](#)

[Top Highlights](#)

[Previous HFSA Coverage on CCKB](#)

Day-of Conference Reports

1. [HFSA Day #1 Highlights](#)
2. [HFSA Day #2 Highlights](#)
3. [HFSA Day #3 Highlights](#)
4. [HFSA Day #4 Highlights](#)

Top Highlights

1. [Opportunities, challenges, and practical pearls for GDMT](#): Emerging therapies in patients with overweight or obesity and HFpEF
2. [Elevated endogenous insulin and insulin resistance may explain links to diastolic dysfunction](#) and negative cardiovascular outcomes in diabetes
3. [A surge in obesity-related pulmonary hypertension](#) and right heart failure deaths stresses a need for aggressive weight management and CV risk reduction
4. [The intersection of CKD, diabetes, and heart failure-related mortality](#) has distinct prevalence patterns across sex, age, and region
5. [HFSA 2025's Exhibit Hall opens](#) with enthusiasm, buffets, interactive displays, and pickleball!
6. [Further findings from FINEARTS-HF](#): Finerenone is as effective for patients at highest risk of cardiovascular events as for those at lower risk
7. [HFSA celebrates 30-year anniversary](#) with a captivating presidential address, roundtable on the future of HF, and keynote on AI in precision care
8. [Semaglutide lowers one-year mortality and hospitalizations](#) in people with HFrEF and obesity, with or without T2D
9. [In large-scale analysis, SGLT-2 inhibitors demonstrate robust cardiovascular benefit](#) and suggest continued need for side effect screening
10. [BalanceD-HF](#): An ongoing phase 3 study to evaluate the effect of balcinrenone and dapagliflozin therapy for patients with HF and impaired kidney function
11. [Treating cardio-kidney-metabolic syndrome](#) to prevent and manage heart failure
12. [Tirzepatide is associated with improved cardiorenal outcomes](#) in patients with HFpEF and moderate-to-severe

CKD

13. [Dapagliflozin and empagliflozin demonstrate similar efficacy for cardiovascular outcomes in T2D](#) besides HF-related hospitalization, where dapagliflozin takes the lead
14. [Finerenone improves HF outcomes and quality of life](#), but some concerns of hyperkalemia and severe adverse events persist
15. [Gestational diabetes in mothers with peripartum cardiomyopathy](#) increases need for certain cardiac interventions but lowers risk of acute kidney injury
16. [The CONFIDENCE trial](#): Simultaneous initiation of additive therapies confers short- and long-term benefits to monotherapy
17. [Secondary analysis of the SUMMIT trial](#): Tirzepatide offers consistent benefit across heart failure stages regardless of sex-based physiological differences
18. [Early GLP-1 RA discontinuation](#) is associated with increased risks of one-year mortality, acute HF events, and HF-associated hospitalization during treatment
19. [Metformin for the heart](#): A new cardioprotective role
20. [Concurrent DKA significantly increases mortality](#) in patients hospitalized for acute heart failure

Previous HFSA Coverage on CCKB

1. [HFSA 2023 Resource Hub](#)
2. [HFSA 2022 Resource Hub](#)
3. [HFSA 2021 Full Report](#)